Britain and America have finalized a landmark trade agreement that will keep no import taxes on UK pharmaceutical exports going into the American market.
Agreement Details of the Accord
As part of the deal, the UK has committed to increase funding on drugs through the public health system. This commitment secures that import taxes on these vital exports will stay at nothing for a timeframe of three years.
This development is in response to previous statements to dramatically increase duties on patented pharmaceutical imports, with figures mentioned reaching 100%.
"This deal with the UK strengthens the international landscape for innovative medicines and establishes long-overdue balance to American-British medicine commerce," an announcement noted.
Economic Significance
Medicines represent one of the UK's largest export categories to the America, which is easily the largest buyer for large British pharmaceutical firms.
Export figures reveal that in the year to the end of last September, the UK sold medicines valued at billions to the US. This figure made up a significant portion of total UK exports in that span.
"This agreement safeguards work, stimulates capital expenditure and paves the way for the UK to become a worldwide center for life sciences," a minister commented.
Key British Pledges
The pact includes several notable changes from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to control costs will be restricted at fifteen percent. Last year, refunds topped 20%.
Industry Background
This agreement follows a protracted dispute between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
The disagreement were heightened by assertions that US customers were charged a premium for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been halted or abandoned, while substantial funding commitments have been directed toward American operations.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
